» Articles » PMID: 34044175

Upgrade Rate of Atypical Ductal Hyperplasia: Ten Years Experience and Predictive Factors

Overview
Journal J Surg Res
Specialty General Surgery
Date 2021 May 27
PMID 34044175
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Atypical ductal hyperplasia (ADH) is a benign epithelial proliferative lesion with histologic features resembling those seen in low grade ductal carcinoma in situ (DCIS). Surgical excision of the biopsy site is the standard management approach. The objective of this study was to determine the upgrade rate from ADH on stereotactic breast biopsies to DCIS or invasive carcinoma (IC) in our institution. We also sought to identify clinical, pathologic and radiologic predictive factors associated with risk of upgrade.

Materials And Methods: Clinical charts, mammograms and pathology reports were reviewed for all women with a stereotactic breast biopsy showing ADH and subsequent surgery at our institution between 2008 and 2018. When available, mammograms were re-reviewed by a radiologist for this study.

Results: 295 biopsies were analyzed in 290 patients. Mean age was 56 y old. Upgrade rate was 10.5% of which 7.5% were DCIS and 3.1% IC. Mammograms were reviewed by a radiologist in 161 patients from 2013 to 2018. In this subset of patients, the rate of upgrade was 8.7% (4.35% DCIS and 4.35% IC). A statistically significant difference he largest size of the microcalcification clusters on mammogram was observed between the upgraded and the non-upgraded subgroups (14.2 mm versus 8.9 mm, P = 0.03) CONCLUSIONS: The evaluation of the largest size of microcalcification clusters on mammogram as a cut-off feature could be considered to choose between an observational versus a surgical approach. This large series provides contemporary data to assist informed decision making regarding the treatment of our patients.

Citing Articles

Trends in Atypical Ductal Hyperplasia Diagnosis and Upgrade: A 20-Year Experience and Impact of MRI Use on Upgrade Rates.

Zaveri S, Sun S, Zaghloul T, Bevers T, Albarracin C, Patel M Ann Surg Oncol. 2025; .

PMID: 39875718 DOI: 10.1245/s10434-025-16933-6.


Long-Term Follow-Up of High-Risk Breast Lesions at Vacuum-Assisted Biopsy without Subsequent Surgical Resection.

Elfgen C, Varga Z, Breitling K, Pauli E, Schwegler-Guggemos D, Kampmann G Breast Care (Basel). 2024; 19(1):62-72.

PMID: 38384485 PMC: 10878709. DOI: 10.1159/000533673.


Third International Consensus Conference on lesions of uncertain malignant potential in the breast (B3 lesions).

Elfgen C, Leo C, Kubik-Huch R, Muenst S, Schmidt N, Quinn C Virchows Arch. 2023; 483(1):5-20.

PMID: 37330436 PMC: 10326140. DOI: 10.1007/s00428-023-03566-x.


Prevalence, Impact, and Diagnostic Challenges of Benign Breast Disease: A Narrative Review.

Fraker J, Clune C, Sahni S, Yaganti A, Vegunta S Int J Womens Health. 2023; 15:765-778.

PMID: 37223067 PMC: 10202205. DOI: 10.2147/IJWH.S351095.


[B3 lesions of the breast: histological, clinical, and epidemiological aspects : Update].

Varga Z, Sinn P, Lebeau A Pathologie (Heidelb). 2023; 44(1):5-16.

PMID: 36635403 PMC: 9877091. DOI: 10.1007/s00292-022-01180-3.